Logo
x

Search

Subscribe Now

bms

BMS’ Opdivo Receives the CHMP’s Positive Opinion as a Neoadjuvant Treatment of Resectable NSCLC

BMS’ Opdivo Receives the CHMP’s Positive Opinion as a Neoadjuvant Treatment of Resectable NSCLC

  • March 31, 2025
BMS Reports the EC’s Approval of Breyanzi to Treat R/R Follicular Lymphoma

BMS Reports the EC’s Approval of Breyanzi to Treat R/R Follicular Lymphoma

  • March 17, 2025
The EC Approves BMS’ Opdivo + Yervoy as 1L Treatment for Hepatocellular Carcinoma

The EC Approves BMS’ Opdivo + Yervoy as 1L Treatment for Hepatocellular Carcinoma

  • March 10, 2025
BMS Reports P-III (CheckMate-816) Trial Data of Opdivo as a Neoadjuvant Treatment of Resectable NSCLC

BMS Reports P-III (CheckMate-816) Trial Data of Opdivo as a Neoadjuvant Treatment of Resectable NSCLC

  • February 19, 2025
BMS Reports Topline Data from P-II (TRANSCEND FL) trial of Breyanzi for R/R Indolent B-cell non-Hodgkin lymphoma

BMS Reports Topline Data from P-II (TRANSCEND FL) trial of Breyanzi for R/R Indolent B-cell non-Hodgkin lymphoma

  • February 11, 2025
BMS’ Opdivo Qvantig SC Injection Secures the US FDA’s Approval for Solid Tumor Opdivo Indications

BMS’ Opdivo Qvantig SC Injection Secures the US FDA’s Approval for Solid Tumor Opdivo Indications

  • December 30, 2024
The US FDA New Drug Approvals in December 2024

    The US FDA New Drug Approvals in December 2024

    • January 14, 2025
    BMS’ Opdivo Qvantig SC Injection Secures the US FDA’s Approval for Solid Tumor Opdivo Indications

      BMS’ Opdivo Qvantig SC Injection Secures the US FDA’s Approval for Solid Tumor Opdivo Indications

      • December 30, 2024
      BMS Reports Topline Data from Two Pivotal P-III Studies of Sotyktu (Deucravacitinib) for Treating Psoriatic Arthritis (PsA)

        BMS Reports Topline Data from Two Pivotal P-III Studies of Sotyktu (Deucravacitinib) for Treating Psoriatic Arthritis (PsA)

        • December 25, 2024
        BMS Reports the EC’s Approval of Opdivo (Nivolumab) Plus Yervoy (Ipilimumab) as a 1L Treatment of MSI-H/dMMR Metastatic Colorectal Cancer (mCRC)

          BMS Reports the EC’s Approval of Opdivo (Nivolumab) Plus Yervoy (Ipilimumab) as a 1L Treatment of MSI-H/dMMR Metastatic Colorectal...

          • December 24, 2024
          BioArctic Collaborates with BMS for its Pyroglutamate-Amyloid-Beta Antibody Programs

            BioArctic Collaborates with BMS for its Pyroglutamate-Amyloid-Beta Antibody Programs

            • December 20, 2024
            BMS’ Opdivo + Yervoy Receives the CHMP’s Positive Opinion as a 1L Treatment of Metastatic Colorectal Cancer

              BMS’ Opdivo + Yervoy Receives the CHMP’s Positive Opinion as a 1L Treatment of Metastatic Colorectal Cancer

              • November 18, 2024
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.